Bavarian Nordic
Bavarian Nordic is a pioneering company focused on the research, development, and manufacturing of innovative life-saving vaccines. The company emphasizes a strong commitment to vaccines, sustainability, and ethical business practices, aiming to create a positive impact on society through its health solutions and responsible operations.
Industries
Nr. of Employees
large (251-1000)
Bavarian Nordic
Hellerup, Denmark (Headquarters)
Patents
Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L
US-12390515-B2
View DetailsMethods and compositions for inducing protective immunity against filovirus infection
US-11918639-B2
View DetailsCombination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
US-11723964-B2
View Details
Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L
US-12390515-B2
View DetailsMethods and compositions for inducing protective immunity against filovirus infection
US-11918639-B2
View DetailsCombination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
US-11723964-B2
View DetailsProducts
Chikungunya vaccine (marketing authorized)
A vaccine product for prevention of chikungunya, granted marketing authorization in multiple jurisdictions.
Freeze-dried smallpox/mpox vaccine (approved)
A freeze-dried formulation of a smallpox/mpox vaccine developed for stockpile and clinical use, with regulatory approvals for use.
Chikungunya vaccine (marketing authorized)
A vaccine product for prevention of chikungunya, granted marketing authorization in multiple jurisdictions.
Freeze-dried smallpox/mpox vaccine (approved)
A freeze-dried formulation of a smallpox/mpox vaccine developed for stockpile and clinical use, with regulatory approvals for use.
Services
Manufacture and supply of vaccine products under GMP for government and commercial customers, including stockpile and preparedness contracts.
Licensing and manufacturing agreements to enable third-party production and expand global access to vaccine products.
Operational conduct of clinical trials including protocol execution, electronic data capture, ePRO implementation, and data management services.
Provision of medical information for marketed products and processes for reporting and managing suspected adverse events.
Commercial partnering, licensing and collaboration to support global distribution and commercialization of vaccine products.
Manufacture and supply of vaccine products under GMP for government and commercial customers, including stockpile and preparedness contracts.
Licensing and manufacturing agreements to enable third-party production and expand global access to vaccine products.
Operational conduct of clinical trials including protocol execution, electronic data capture, ePRO implementation, and data management services.
Provision of medical information for marketed products and processes for reporting and managing suspected adverse events.
Commercial partnering, licensing and collaboration to support global distribution and commercialization of vaccine products.
Expertise Areas
- Vaccine research and development
- GMP vaccine manufacturing
- Clinical trial management
- Clinical data management and biostatistics
Key Technologies
- Vaccine platform development
- Freeze-drying (lyophilization)
- Good Manufacturing Practice (GMP) production
- Electronic patient-reported outcomes (ePRO)
News & Updates
Our financial results for the first three months of 2025 were published on Friday, May 9, 2025.
In recognition of our contribution to Nasdaq’s ESG Data Portal, which provides objective and quantifiable metrics on environmental, social and governance issues to the public as well as present and future investors, we have been Nasdaq ESG Transparency Partner since April 2021.
Our financial results for the first three months of 2025 were published on Friday, May 9, 2025.
In recognition of our contribution to Nasdaq’s ESG Data Portal, which provides objective and quantifiable metrics on environmental, social and governance issues to the public as well as present and future investors, we have been Nasdaq ESG Transparency Partner since April 2021.